We are collaborating with leading biopharmaceutical companies to apply our DCE Platform® to existing compounds with known therapeutic properties, including approved drugs, advanced clinical candidates or previously studied biologically active compounds. In these collaborative programs, incorporating deuterium may enable superior pharmacokinetic or metabolic properties and thereby offer the potential opportunity for best-in-class products with enhanced clinical safety, tolerability or efficacy.
Our clinical pipeline of drug candidates resulting from our DCE Platform includes novel drugs that are being developed with strategic collaborators, which include the following:
|Under our license agreement, Avanir is developing AVP-786, which combines deuterium-substituted dextromethorphan and an ultra-low dose of quinidine. Avanir is conducting several Phase 2 and Phase 3 clinical trials to evaluate AVP-786 for the treatment of neurologic and psychiatric disorders, the most advanced of which are Phase 3 clinical trials for the treatment of agitation associated with Alzheimer’s disease.|
|Jazz Pharmaceuticals and Concert are collaborating to develop JZP-386, a product candidate containing deuterated sodium oxybate for potential use in patients with narcolepsy. Sodium oxybate is the active ingredient in Jazz’s marketed drug Xyrem®. Jazz Pharmaceuticals is exploring formulation options designed to leverage the positive effects observed in the Phase 1 trials.|
|Celgene and Concert are collaborating to develop CTP-730, a product candidate containing deuterated apremilast for the treatment of inflammatory diseases. Concert has completed Phase 1 evaluation of CTP-730. Celgene is currently assessing the data from the Phase 1 program.|
Asset Purchase Agreement
|Under an asset purchase agreement, Vertex acquired worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis. CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis.|
For partnership inquiries, please contact: